GlassScriptPhysician profile
Vincent J Lee
NPI 1235148495
$3,703.56
in general payments reported to CMS, 2019-2025
26 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $154 · 2021: $781 · 2022: $988 · 2023: $591 · 2024: $383 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,363.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,040.97 | 2019-2023 | Kyprolis, Xgeva, Nplate |
| Merck Sharp & Dohme LLC | $463.17 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Astrazeneca Pharmaceuticals LP | $413.32 | 2019-2025 | Enhertu, Calquence, Lynparza |
| Novartis Pharmaceuticals Corporation | $320.73 | 2019-2025 | |
| Seagen INC. | $230.14 | 2020-2023 | Tivdak |
| Abbvie INC. | $204.15 | 2019-2025 | |
| Genentech USA, INC. | $97.15 | 2022-2025 | Polivy, Venclexta |
| Lilly USA, LLC | $87.79 | 2022-2024 | Verzenio, Jaypirca |
| Janssen Biotech, INC. | $76.64 | 2023-2025 | Akeega, Erleada, Balversa |
| Daiichi Sankyo INC. | $70.68 | 2019-2023 | Enhertu |
| Varian Medical Systems, INC. | $67.03 | 2019 | |
| Eisai INC. | $66.24 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $59.74 | 2024 | Onivyde |
| Taiho Oncology, INC. | $59.03 | 2019-2023 | |
| Reflexion Medical, INC. | $56.25 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $56.25 | 2022-2025 | |
| Springworks Therapeutics, INC. | $55.50 | 2024-2025 | Ogsiveo |
| Bayer Healthcare Pharmaceuticals INC. | $45.78 | 2022 | |
| Puma Biotechnology, INC. | $45.55 | 2021-2025 | |
| Blue Earth Diagnostics | $45.27 | 2021-2024 | |
| Astellas Pharma US INC | $40.72 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $34.81 | 2019 | |
| Rigel Pharmaceuticals, INC. | $22.69 | 2022 | |
| Gilead Sciences, INC. | $16.07 | 2024 | |
| Incyte Corporation | $14.00 | 2023 | Jakafi |
| Focal Therapeutics, INC. | $13.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.